Comparative Pharmacology
Head-to-head clinical analysis: DERMA SMOOTHE FS versus FLUOCET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DERMA SMOOTHE FS versus FLUOCET.
DERMA-SMOOTHE/FS vs FLUOCET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluocinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit pro-inflammatory cytokines and reduce inflammation, vasodilation, and edema.
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by blocking the reuptake of serotonin into presynaptic neurons.
Apply topically as a thin film to affected areas twice daily. Maximum weekly dose should not exceed 60 g.
20 mg orally once daily in the morning.
None Documented
None Documented
Terminal elimination half-life: 24-36 hours (systemic absorption after topical application); clinical context: prolonged with hepatic impairment.
Fluoxetine: 4-6 days (single dose), 4-6 days (chronic); Norfluoxetine: 16 days. Clinical context: Steady state achieved after 4-5 weeks; extended half-life reduces withdrawal risk but prolongs washout.
Primarily renal (90%) as inactive metabolites; <5% unchanged. Biliary/fecal excretion accounts for <10%.
Renal: 80% as fluoxetine and its metabolites (60% as glucuronide conjugates, 20% as parent and norfluoxetine). Fecal: 15% (biliary).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid